TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Sandostatin for Patients With Androgen Independent Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed adenocarcinoma of the prostate.~* Biochemical disease progression following androgen deprivation and therapy with at least one antiandrogen defined as three rises in PSA with PSA determinations at least 4 weeks apart and each PSA value \> 0.2 ng/ml.~* Four weeks since prior therapy with Flutamide.~* Six weeks since prior therapy with Bicalutamide or Nilutamide.~* Current PSA \> 5 ng/ml.~* Testosterone \<50 ng/dL.~* SGPT (ALT) \< 1.5 times upper limit of normal.~* Fasting blood glucose \> 60 mg/dL.~* ECOG performance status 0, 1 or 2.~* No visceral or bony metastatic disease (Lymph node only metastases are allowed).~* No prior chemotherapy for prostate cancer.~* No current treatment with insulin or an oral hypoglycemic.~* No history of treatment with octreotide analogs for prostate cancer.~* No NYHA Class 3 or 4 cardiac status.~Exclusion Criteria:~* Diabetes Mellitus requiring medical therapy and/or that which is not controlled by dietary means (HbA1C\<6.0).~* A history of gallstones that has been clinically significant. Patients who have undergone cholecystectomy are eligible.~* Other concomitant medical or psychiatric condition which would make it undesirable, in the physician's opinion, for the patient to participate in the protocol or would jeopardize compliance with the protocol requirements.~* Prior treatment with chemotherapy for prostate cancer.~* No current treatment with Saw Palmetto, or Proscar. Patients must be off these medicines for more than 4 weeks.

- Gender: MALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Capturing BRCA1/2 Mutational Status in Women With High Grade Serous Ovarian Cancer and Impact on Clinical Outcome.

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with high grade serous carcinoma originating from the ovaries, fallopian tube or peritoneal cavity; subtype of high grade endometrioid and clear cell ovarian cancer could be eligible in the exploratory cohort~* Patient must be ≥18 years old~* All patients must have sufficient archival tumor tissue for molecular analysis~* All patients must consent to have a genetic testing~* All patients must have signed and dated an informed consent form~Exclusion Criteria:~· Other histology subtype

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Dynamic CT Myocardial Perfusion Imaging

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Referral for cardiac hybrid imaging with CCTA and SPECT~* Male and Female subjects 18 years of age or older,~* Written informed consent by the participant after information about the project~Exclusion Criteria:~* Contraindications for CCTA (including renal failure with a GFR \<60ml/min/1.73m2, allergies to ionidated constrast agents)~* Inability to follow the examination procedure due to language barriers, mental disease, dementia etc.~* Pregnancy or breast feeding~* Known allergies to iodinated contrast agent (Visipaque ®), 99mTc-Tetrofosmin (Myoview ®), betablockers (Beloc i.v. ®) or nitrates (Isoket -Spray®)~* Hypersensitivity to adenosine~* Asthma bronchiale

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CTP and SPECT-MPI (Type: OTHER): Every patient enrolled will undergo CT-MPI and SPECT-MPI. The latter is clinically indicated,.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: An Extension Study of KCT-0809 in Dry Eye Patients With Sjögren's Syndrome

Study Design Characteristics:
- Allocation: N/A
- Intervention Model: N/A
- Observational Model: N/A
- Primary Purpose: N/A
- Time Perspective: N/A
- Masking: N/A
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Dry eye patients with Sjögren's syndrome finished KCT1301 study~Exclusion Criteria:~* Patients with poor adherence to medication of study drug in KCT1301 study

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: None

Study Arms:
- KCT-0809 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Cranoc Lipid Study in Renal Transplantation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients (18 - 65, inclusive)~* cadaver and living kidney transplantation (1. Ntx, 2. Ntx)~* LDL-cholesterol ≤ 130mg/dl (-3 Mo until start of Tx)~* Patients with a history of Myocard infarct: LDL-Cholesterol ≤ 110mg/dl~* Immunsuppression: Tacrolimus in combination with steroids or Mycophenolat Mofetil~* patients indulgence~Exclusion Criteria:~* statin before the study~  * LDL-Cholesterol \>130mg/dl before transplantation~ * Instabil Angina, Myocard infarct \<6 months before transplantation~ * symptomatic Hypothyreosis~ * child bearing, lactating~ * elavated liver encymes (\> 2x elavated: AST, ALT, bilirubine, PCK)~ * Fibrates are not allowed~ * multiorgantransplantation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- A (therapy with fluvastatin 80mg retard) (Type: NO_INTERVENTION): kidney transplants receive in addition fluvastatin 80mg retard for 3 years
- B (Type: PLACEBO_COMPARATOR): no therapy with fluvastatin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Computer-Assisted Fixation of Trochanteric Femur Fractures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~1. Patients aged 18 years and older with isolated closed peritrochanteric femur fractures who are candidates for surgical fixation with a cephalomedullary nail device~Exclusion criteria:~1. Patients with open peritrochanteric femur fractures or multiple injuries (i.e., polytrauma)~2. Patients with peritrochanteric femur fractures better treated with a device other than a cephalomedullary nail, as determined by the attending orthopedic surgeon~3. Patients less than 18 years of age

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Traditional fluoroscopy (Type: ACTIVE_COMPARATOR): Cohort 1 will consist of patients with closed peritrochanteric femur fractures who undergo open reduction internal fixation with a Stryker© Gamma™ cephalomedullary nail using traditional fluoroscopy for insertion of the lag screw (current standard of care).
- Stryker© ADAPT™ platform (Type: EXPERIMENTAL): Cohort 2 will consist of patients with closed peritrochanteric femur fractures who undergo open reduction internal fixation with a Stryker© Gamma™ cephalomedullary nail using the Stryker© ADAPT™platform to assist with insertion of the lag screw.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Effects of the Quantity of Repetitive Transcranial Magnetic Stimulation(rTMS) on the Recovery After Stroke

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* single mono-hemispheric ischemic or hemorrhagic stroke~* 1st onset stroke patient~* Upper extremity functional deficit attributable to acute stroke~* A stage of at least 3 on brunnström pre-treatment~* Written signed consent~Exclusion Criteria:~* Multiple lesion~* Bilateral cortical lesion and motor problems~* Cerebellar, or brainstem lesions~* History of more than one stroke~* Uncontrolled medical problems, such as: cardiopulmonary disease, severe rheumatoid arthritis, active joint deformity of arthritic origin, active cancer, or renal disease;~* Increased intracranial pressure~* History of seizure confirmed by interview and medical chart review~* Any individual who is on medication which is known to lower seizure threshold~* Other conditions that increase the risk of side effects due to rTMS procedures: a metal plate or metal object in the skull or eye, intracardiac line, increased intracranial pressure, cardiac pacemaker, implanted medication pump, tricyclic antidepressants, neuroleptics, history of seizure in the immediate family~* An age of less than 20 years old~* Any current actively treated medical or surgical condition or neurological or psychiatric illness other than stroke~* Complications that would prevent participation in the intervention, such as severe pain and severe spasticity~* Inability to cooperate outcome measure-related task~* Severe language disturbances~* Serious cognitive deficits~* Non-vascular cause for the neurological symptoms other central nervous system~* Disorder or peripheral neuropathy of the upper extremity~* Taking medication which interrupt brain activity~* Women who are pregnant

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Sham rTMS-Sham rTMS (Type: SHAM_COMPARATOR): Sham rTMS for 2 weeks
- Sham rTMS-Real rTMS (Type: EXPERIMENTAL): Sham rTMS in the first week and real rTMS in the second week
- Real rTMS-Real rTMS (Type: EXPERIMENTAL): Real rTMS for 2 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Response Rate of PROCRIT (Epoetin Alfa) Given at a Dose of 40,000 Units Once a Week to Cancer Patients With Anemia Who Are Not Receiving Chemotherapy.

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed diagnosis of non-myeloid malignancy~* Baseline hemoglobin value of less than or equal to 11 g/dL unrelated to transfusion~* Patients must not be receiving or planning to receive chemotherapy or radiotherapy within the 16-week study period. However, patients receiving hormonal therapy or non-myelosuppressive therapies are allowable~* Female patients with reproductive potential must have a negative serum pregnancy test at screening.~Exclusion Criteria:~* Uncontrolled hypertension~* History (within 6 months) of uncontrolled cardiac arrhythmias, or history of pulmonary emboli, deep vein thrombosis, ischemic stroke, other arterial or venous thrombotic events (excluding superficial thromboses), or known history of chronic coagulation disorder~* Transfusion within 28 days prior to first dose~* Planned chemotherapy or radiation during study and no prior chemotherapy within 8 weeks or radiation within 4 weeks of study entry~* No prior treatment with Epoetin alfa or any other erythropoietic agent within the previous two months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Botulinum Toxin A in the Treatment of Bruxism-related Symptomatology

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient who has given written consent.~* Patient between 18 and 64 years of age.~* Patient who has never received botulinum toxins~* Symptomatic patient in the context of bruxism in failure to the usual treatments (analgesic, physiotherapy, relaxation technique and maxillary retainer)~* Woman of childbearing age using an effective method of contraception~* Symptomatic patients in the context of bruxism, without a maxillary disocclusion retainer.~Exclusion Criteria:~* Protected Adult~* Patient not affiliated to the national health insurance system~* Pregnant or breastfeeding woman~* Refusal to take part in the study~* Neuromuscular diseases, including Myasthenia gravis, Myopathies, Amyotrophic Lateral Sclerosis. Lambert-Eaton Syndrome, patients with peripheral motor neuropathies, patients with underlying neurological disorders.~* Patients with a history of cardiovascular disease~* Patients with epilepsy or a previous seizure episode~* Neurogenic impairment of the face (including facial paralysis, polyradiculoneuritis)~* History of dysphagia or pulmonary aspiration~* Injection site infection (masseter and temporal)~* Hypersensitivity or allergy to botulinum toxin or any of its excipients.~* Treatment with aminoglycosides or anticholinesterase agents.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Symptomatic patients in the context of bruxism (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Systemic Treatments of Bone Metastases From Kidney Cancer in Patients Treated With Targeted Therapies

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years.~* Histologically proven mRCC.~* Administration of one of the systemic agents in use for the treatment of mRCC (no more than three prior systemic therapy regimens). Patients with at least 6 months of 1st line treatment and a bone event may be included.~* More than 1 bone metastasis.~* Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) ≤ 2.~* Adequate renal function (serum creatinine ≤ 200 mmol/L or creatinine clearance ≥ 30 mL/min according to Cockroft formula or MDRD formula for patients older than 65 years).~* Covered by a medical insurance.~* Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.~* Signed informed consent.~* Accepting to use effective contraception during study treatment and within 5 months after final dose of study therapy.~Exclusion Criteria:~* Prior bisphosphonate or denosumab treatment in the year before inclusion.~* Imminent or ongoing nerve or spinal compression as per the investigator's judgement.~* Ongoing first-line therapy, started for less than 6 months (patients with BM at time of metastases diagnosis will initially benefit from the angiogenesis targeted agents used and are not at higher risk).~* Anticancer treatment under investigation.~* Paraneoplastic hypercalcemia (corrected total calcium \> 2.7 mmol/L).~* Grade 4 toxicity under previous targeted agents.~* Liver failure (AST and/or ALT ≥ 5.0 x upper limit of normal (ULN) or total bilirubin beyond normal limits).~* Severe hypocalcaemia \> 2.8 mmol/l.~* Fructose intolerance.~* Invasive dental procedure (i.e. tooth extraction, dental implants, oral surgery) within the 10 days prior to randomization or required dental procedures at the pre-inclusion dental examination.~* Psychological, familial, sociological, geographical conditions that would limit compliance with study protocol requirements.~* Pregnant or breastfeeding woman. Females of child-bearing potential must have a negative serum pregnancy test within 7 days prior inclusion.~* Life expectancy ≤ 3 months.~* Participation to another clinical trial that might interfere with the evaluation of the main criterion.~* Known hypersensitivity to the active substance or to any of the excipients of bisphosphonate or denosumab.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: EXPERIMENTAL): bone targeted treatment (denosumab or zoledronic acid)
- Arm B (Type: NO_INTERVENTION): no specific treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of the Safety and Tolerability of PG545 in Patients With Advanced Solid Tumours

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age \>=18 years.~* Histological or cytological documentation of non hematologic, malignant solid tumour.~* Have failed at least one previous therapeutic regimen.~* Measurable disease according to RECIST 1.1.~* Life expectancy \>= 12 weeks~* ECOG Performance Status of 0 or 1~* Written, signed and dated informed consent~* Able and willing to meet all protocol-required treatments, investigations and visits.~* Have adequate organ function~Exclusion Criteria:~* Clinically significant non-malignant disease.~* Active CNS metastases.~* Subjects with uncontrolled diabetes.~* History of clinically significant adverse drug reaction to heparin or other anti-coagulant agents~* History of immune-mediated thrombocytopaenia or other platelet abnormalities or other hereditary or acquired coagulopathies.~* Concomitant use of aspirin (\> 150 mg/day), NSAIDs (except COX-2 selective inhibitors), vitamin K antagonists (other than low-dose prophylactic use), heparin within two weeks prior to randomisation, or other anti-platelet drugs.~* History of severe allergic, anaphylactic or other significant adverse reaction to radiographic contrast media~* Known seropositivity to the human immunodeficiency virus (HIV)~* Women who are pregnant or breast-feeding.~* Women of child-bearing potential and male subjects who are partners of women of childbearing potential who are unable or unwilling to practice a highly effective means of contraception.~* Active substance abuse~* Subjects who have received an investigational agent within 28 days prior to Cycle 1 Day 1.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PG545 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Study of Evobrutinib in Participants With RMS

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participants diagnosed with RMS (relapsing-remitting multiple sclerosis \[RRMS\] or secondary progressive multiple sclerosis \[SPMS\] with relapses) in accordance with 2017 Revised McDonald criteria (Thompson 2018).~* Participants with one or more documented relapses within the 2 years before Screening with either: a. one relapse which occurred within the last year prior to randomization, OR b. the presence of at least 1 gadolinium-enhancing (Gd+) T1 lesion within 6 months prior to randomization.~* Participants have EDSS score of 0 to 5.5 at Baseline. Participants with an EDSS score \<= 2 at screening are only eligible for participation if their disease duration (time since onset of symptoms) is no more than 10 years.~* Participants are neurologically stable for \>= 30 days prior to both screening and baseline.~* Female participants must be neither pregnant nor breast-feeding and must lack child-bearing potential, as defined by either: post-menopausal or surgically sterile or use an effective method of contraception for the duration of the study.~* Participants have given written informed consent prior to any study-related procedure.~* Other protocol defined inclusion criteria could apply~Exclusion Criteria:~* Participants diagnosed with Progressive MS, in accordance with the 2017 Revised McDonald criteria as follows: a). Participants with Primary Progressive MS. b). Participants with secondary progressive MS without evidence of relapse.~* Disease duration more than (\>) 10 years in participants with an EDSS =\< 2.0 at screening.~* Immunologic disorder other than MS, or any other condition requiring oral, intravenous (IV) , intramuscular, or intra-articular corticosteroid therapy, with the exception of well-controlled Type 2 diabetes mellitus or well controlled thyroid disease.~* Other protocol defined exclusion criteria could apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Evobrutinib + Avonex® matched Placebo (Type: EXPERIMENTAL): Participants received active evobrutinib twice daily (BID) along with concomitant intramuscular (IM) injection of placebo matched to Avonex® once a week. Treatment period was planned to be of 96 weeks.
- Avonex® + Evobrutinib matched Placebo (Type: ACTIVE_COMPARATOR): Participants received IM injection of active Avonex® once a week along with concomitant placebo matched to evobrutinib BID. Treatment period was planned to be of 96 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy